Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Small molecule toll-like receptor (TLR) antagonists

a toll-like receptor and small molecule technology, applied in the field of immunology, can solve the problems of protective or adverse physiologic outcomes of the hos

Inactive Publication Date: 2007-10-04
COLEY PHARMA GMBH +1
View PDF44 Cites 88 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is based on the discovery of small molecules that can inhibit TLR-mediated immunostimulation, which is involved in various conditions such as autoimmunity, inflammation, allergies, asthma, graft rejection, and cancer. These molecules can be used as pharmaceutical agents to treat these conditions by inhibiting TLR-mediated signaling. The invention provides methods for using these molecules to alter TLR-mediated signaling in response to a TLR ligand or agonist. The small molecules can also be combined with other agents to achieve a synergistic effect on TLR-mediated immunostimulation."

Problems solved by technology

Stimulation of the immune system, which includes stimulation of either or both innate immunity and adaptive immunity, is a complex phenomenon that can result in either protective or adverse physiologic outcomes for the host.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Small molecule toll-like receptor (TLR) antagonists
  • Small molecule toll-like receptor (TLR) antagonists
  • Small molecule toll-like receptor (TLR) antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

In Vitro Screening of a Library of Small Molecules for Inhibitors of Human TLR9

[0470] Candidate small molecules for initial screening were obtained from a commercially available library of 880 off-patent small molecules selected for structural diversity and proven bioavailability in humans (Prestwick Chemical Library). Human embryonic kidney HEK293 cells stably transfected with a human TLR9 (hTLR9) expression vector were incubated overnight in the presence of 50 nM CpG ODN 2006 (i.e., the EC50 concentration of ODN 2006) and selected small molecule candidate compounds at different concentrations ranging from 5×10−7 M to 5×10−5 M. TLR9 activity was assayed in terms of induction of a 6× NF-κB-luciferase reporter construct cotransfected in the cells. Results were measured as fold induction over baseline luciferase activity measured in the absence of ODN 2006 and compared to fold induction over baseline in the presence of the EC50 concentration of ODN 2006 alone. From this initial scree...

example 2

In Vitro Screening of a Library of Small Molecules for Inhibitors of Human TLR8

[0482] Candidate small molecules for initial screening were identified in an assay similar to that in Example 1 except HEK293 cells were stably transfected with a human TLR8 (hTLR8) expression vector and incubated overnight in the presence of 500 nM R848 (EC50 of R848 for TLR8) and selected small molecule candidate compounds at different concentrations ranging from 5×10−7 M to 5×10−5 M. TLR8 activity was assayed in terms of induction of a 6×NF-κB-luciferase reporter construct cotransfected in the cells. Results were expressed as fold induction over baseline luciferase activity measured in the absence of R848. From this initial screening a number of small molecules were identified as lead compounds and were categorized by structure and activity. Additional screening was performed in like manner using additional small molecules selected from another library or specifically prepared for this purpose. Result...

example 3

In Vitro Screening of a Library of Small Molecules for Inhibitors of Human TLR7

[0483] Candidate small molecules for initial screening were identified in an assay similar to that in Example 1 except HEK293 cells were stably transfected with a human TLR7 (hTLR7) expression vector and incubated overnight in the presence of 2 μM R848 (EC50 of R848 for TLR7) and selected small molecule candidate compounds at different concentrations ranging from 5×10−7 M to 5×10−5 M. TLR7 activity was assayed in terms of induction of a 6×NF-κB-luciferase reporter construct cotransfected in the cells. Results were expressed as fold induction over baseline luciferase activity measured in the absence of R848. From this initial screening a number of small molecules were identified as lead compounds and were categorized by structure and activity. Additional screening was performed in like manner using additional small molecules selected from another library or specifically prepared for this purpose. Results ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
half lifeaaaaaaaaaa
half lifeaaaaaaaaaa
mean body weightaaaaaaaaaa
Login to View More

Abstract

The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

Description

RELATED APPLICATIONS [0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application Ser. No. 60 / 556,007, filed Mar. 23, 2004, and U.S. provisional patent application Ser. No. 60 / 480,588, filed Jun. 20, 2003, the entire contents of both of which are incorporated herein by reference.FIELD OF THE INVENTION [0002] The invention relates to generally to the field of immunology. More particularly, the invention relates to compositions and methods for altering immune function. More specifically, the invention relates to compositions and methods for affecting immune stimulation mediated through Toll-like receptor (TLR) molecules. BACKGROUND OF THE INVENTION [0003] Stimulation of the immune system, which includes stimulation of either or both innate immunity and adaptive immunity, is a complex phenomenon that can result in either protective or adverse physiologic outcomes for the host. In recent years there has been increased interest in the mechanisms...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/519A61P37/00C07D239/70C12N5/00A01N43/54A61K31/517C07D239/72C07D471/00C07K
CPCA61K31/122A61K31/382A61K31/437A61K31/4462A61K31/4709A61K31/496C07D405/12A61K31/5415A61K31/55A61K31/553C07D221/10C07D239/94C07D239/95A61K31/517A61P1/04A61P13/00A61P17/00A61P17/06A61P19/02A61P21/00A61P25/00A61P35/00A61P37/00A61P37/02A61P37/06A61P43/00A61P9/00
Inventor LIPFORD, GRAYSONFORSBACH, ALEXANDRAZEPP, CHARLES
Owner COLEY PHARMA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com